Comparative Pharmacology
Head-to-head clinical analysis: AFAXIN versus TAZAROTENE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AFAXIN versus TAZAROTENE.
AFAXIN vs TAZAROTENE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inhibitor of the sodium-dependent serotonin reuptake transporter (SERT), increasing serotonin levels in the synaptic cleft.
Tazarotene is a retinoid prodrug that is converted to its active metabolite, tazarotenic acid, which binds to retinoic acid receptors (RAR-β, RAR-γ) with high affinity, modulating gene expression involved in cell proliferation, differentiation, and inflammation.
500 mg orally twice daily
Topical: Apply a pea-sized amount to affected areas once daily in the evening. For plaque psoriasis, use 0.05% or 0.1% gel or cream. For acne vulgaris, use 0.1% cream or 0.045% or 0.1% lotion.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in healthy adults, allowing twice-daily dosing; prolonged in renal impairment (up to 30 hours).
Clinical Note
moderateTazarotene + Deferasirox
"The serum concentration of Deferasirox can be increased when it is combined with Tazarotene."
Clinical Note
moderateVenlafaxine + Desmopressin
"The risk or severity of adverse effects can be increased when Venlafaxine is combined with Desmopressin."
Clinical Note
moderateDesvenlafaxine + Desmopressin
"The risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Desmopressin."
Clinical Note
moderateTazarotene + Teriflunomide
Terminal elimination half-life of tazarotenic acid is 7–12 hours in healthy subjects; clinically, steady-state is achieved within 14 days.
Renal excretion accounts for approximately 60-70% of the administered dose as unchanged drug; biliary/fecal elimination accounts for 20-25% with the remainder as metabolites.
Primarily fecal (approximately 60%) and urinary (approximately 13%) as metabolites; unchanged drug not detected in urine.
Category C
Category D/X
Retinoid
Retinoid
"The metabolism of Teriflunomide can be decreased when combined with Tazarotene."